Agila Biotech and Pfenex make biosimilars deal

Biosimilares/Novedades | Posted 17/05/2013 post-comment0 Post your comment

Agila Biotech, a subsidiary of India-based Strides Arcolab, and US-based biotech firm Pfenex announced on 16 April 2013 that they had entered into a joint venture for biosimilars.

The companies will develop, manufacture and commercialize an initial pipeline of six biosimilar products for the global market. They identified their first target as a biosimilar of multiple sclerosis treatment Betaseron (interferon beta-1b), which they expect to be in human clinical trials by Q4 2013.

Pfenex will assume primary responsibility for development of an optimized production strain, process and analytical package for each product, while Agila Biotech will be responsible for preclinical and phase I development, as well as manufacturing, according to good manufacturing practice requirements. The joint venture will then progress the products through phase III and into commercialization. Manufacture of the collaboration products will be carried out at Agila Biotech’s state-of-the-art manufacturing facility being built with Bio-XCell in Malaysia.

Manufacturing the biosimilars in Malaysia was seen to not only be cheaper, but also provide a gateway for high quality, cost-effective biologicals into Asia and the Organisation of Islamic Cooperation (OIC) region, which are currently underserved.

This is not the first biosimilars collaboration that Pfenex has entered into. Back in 2010 the company made an agreement with Ranbaxy Laboratories to develop an undisclosed biosimilar using the company’s Pfenex Expression Technology platform, a pseudomonas-based recombinant protein expression technology.

Related articles

Mylan to acquire Strides Arcolab’s injectable generics business

Biotech growth and biosimilar opportunities in India

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Pfenex, Strides Arcolab

comment icon Comments (0)
Post your comment
Related content
La FDA aprueba el biosimilar de bevacizumab Avzivi
Cancer Cell V13I20
Biosimilares/Novedades Posted 30/01/2024
La FDA aprueba el biosimilar pegfilgrastim Stimufend
Biosimilares/Novedades Posted 07/10/2022
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010